197 results about "Immune complex" patented technology

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.

The invention relates to the technical field of bacterium detection, in particular to a colorimetric-Raman coding immunochromatography test strip based on a 3D film-shaped SERS probe and a multi-bacterium detection method thereof. According to the technical scheme, the kit comprises a sample pad, a nitrocellulose membrane, a water absorption pad, a 3D membrane-like SERS probe and an operation buffer solution. According to the present invention, the immunochromatography of the 3D film-like probe is provided, the MoDAu-coated Ag SERS nano-film is adopted as the probe in the system, such that the pathogenic bacteria can be highly specifically recognized and captured, the immune complex fluidity can be increased, the rapid quantitative detection of the three pathogenic bacteria can be achieved, and the flexible 3D film-like SERS probe capable of enhancing the colorimetric ability and the SERS activity and highly specifically capturing the pathogenic bacteria can be prepared; by combining with an antibody-modified ICA test strip, rapid, simultaneous and quantitative determination of various pathogenic bacteria is realized.

Provided is a method of testing an analyte in a sample. The method comprises: causing a first proximity probe and a second proximity probe to bind to an analyte in a sample in sequence to form an immune complex, the immune complex being captured on a solid-state matrix by means of binding of the first proximity probe to a capture probe, and adding a blocker after the first proximity probe binds to the capture probe and before the second proximity probe is added, the blocker binding to the capture probe to reduce non-specific binding of the capture probe to molecules other than the immune complex. Also provided is a blocker for the method.

The invention discloses a confinement composite nano-enzyme enhanced electrochemiluminescence immunosensor for detecting tumor necrosis factors and a construction method and application of the immunosensor. The immunosensor is a three-electrode system, and liquid to be detected contains luminol; wherein the working electrode is obtained by covalently immobilizing a tumor necrosis factor specific antibody after an SNF epoxy modified electrode is subjected to confinement of Ni (OH) 2-CeO2 composite nano-enzyme and then closing a non-specific site. The Ni (OH) 2-CeO2 composite nano-enzyme is confined in a nano-channel, the Ni (OH) 2-CeO2 composite nano-enzyme and the nano-channel can synergistically accelerate the process of an oxygen reduction reaction, the modification stability of the nano-enzyme is effectively improved, and a formed immune complex causes increase of interface resistance and steric hindrance of a sensing electrode to cause signal reduction; therefore, high-sensitivity detection of the tumor necrosis factor is realized, and the constructed sensor has the advantages of low detection limit, wide detection range and the like, and is very suitable for being widely applied to the fields of auxiliary clinical diagnosis, large-scale screening, health monitoring and the like.

A reagent combination, a kit, a detection system and a detection method for detecting a small molecule substance. In the condition that a solution to be tested does not contain or contains a small amount of the small molecule substance, an antibody binds to a substrate protein conjugate to form an immune complex, a stem-loop structure is generated by means of a complementary pairing among a plurality of nucleic acid molecules, a first fluorescent group excites a second fluorescent group to emit a second fluorescence on the basis of fluorescence resonance energy transfer, and the content of the small molecule substance is calculated. In the condition that the solution to be tested contains a large amount of the small molecule substance, the immune complex and the stem-loop structure cannot be formed, and the second fluorescent group cannot emit the second fluorescent.

The invention discloses a chimeric antigen receptor modified cell drug as well as a preparation method and application thereof, and belongs to the technical field of cell drugs. A cell drug is obtained by introducing a chimeric antigen receptor targeting B cells and / or plasma cells into in-vitro or in-vivo immune cells through a gene delivery system, and target spots of the targeted B cells and / or plasma cells comprise CD19, BCMA, CD20, CD22, CD38, CD138, GPRC5D and SLAMF7. The chimeric antigen receptor modified cell drug can realize specific recognition of B cells and / or plasma cells and activate immune cells through a specific single-chain antibody fragment (scFv), and can specifically remove the B cells in vitro and in vivo, thereby preventing the generation of autoimmune antibodies and the formation of immune complexes, achieving the purpose of thoroughly treating diseases, and having good application prospects. The life quality of a patient is improved, the disease is finally cured, and the application potential and the commercial value are huge.

The invention discloses a biochemical immunodetection device and a biochemical immunodetection method for ursodesoxycholic acid reduzate, and belongs to the technical field of ursodesoxycholic acid reduzate detection. The ursodesoxycholic acid reduzate detection device comprises a detection box and a lifter at the bottom of the detection box, a dissolution preparation part and a centrifugal part are arranged in the detection box, and the dissolution preparation part can fully dissolve an ursodesoxycholic acid reduzate-containing medicament; the centrifugal part is used for carrying out precipitation separation on the dissolved medicament; the detector can accurately collect fluorescence signals of the immune complex; according to the ursodesoxycholic acid reduzate detection device, the integrated operation of detection test tube fixing, cover opening and transferring, medicament adding, cover closing and plug sealing and dissolving is achieved, the steps of automatic medicament filling, sealing and the like are achieved, the medicament preparation efficiency is greatly improved, efficient and accurate detection of ursodesoxycholic acid reduzate is further achieved, and the detection efficiency is improved. And complex and tedious manual operation is avoided, and the situation that the sample is easily polluted by manual operation is avoided.

The present invention discloses a cleaning device and a chemiluminescent immunoassay analyzer having the same, wherein the cleaning device comprises a frame and a conveying mechanism, a cleaning needle mechanism, and a magnet mechanism arranged on the frame, wherein the frame is provided with a liquid aspiration station and a liquid injection station; the conveying mechanism comprises a turntable and a first driving assembly capable of driving the turntable, wherein the turntable is provided with a cup placement hole for placing a reaction cup, the conveying mechanism can transport the reaction cup to different stations, and the turntable can reciprocate; the cleaning needle mechanism corresponds to the liquid aspiration station and the liquid injection station and can absorb waste liquid from the reaction cup and inject cleaning liquid into the reaction cup; the magnet mechanism comprises at least one active magnet assembly arranged corresponding to the liquid aspiration station, and the active magnet assembly can adsorb the immune complex in the reaction cup to the cup wall and can drive it to move upward. The present invention has a good washing and separation effect on the immune complex and a high working efficiency.

The invention provides a method for rapidly detecting fluorescently-labeled allergens for hygienic products, and relates to the technical field of detection of hygienic products. The rapid fluorescently-labeled allergen detection method for the hygienic products comprises the following steps: combining a fluorescently-labeled substance with an allergen specific antibody through a chemical coupling method to form a stable fluorescently-labeled antibody compound; fixing the fluorescence labeled antibody on the surface of a reaction chamber of a micro-fluidic chip; introducing a hygienic product sample or an extract thereof into the chip, and combining the hygienic product sample or the extract thereof with the fixed fluorescently-labeled antibody to form an'allergen-antibody-fluorescently-labeled 'immune complex; a detection area is irradiated by an excitation light source, fluorescence intensity is monitored in real time by a photoelectric sensor, and a detection result is generated by combining a data analysis module. According to the invention, the rapid and high-sensitivity detection of allergens in hygienic products is realized by combining a fluorescence labeled antibody with a microfluidic technology.

The present disclosure concerns a microfluidic method of assaying antibody secreting cells (ASCs), comprising the steps of isolating ASCs within droplets such that each droplet encapsulates only one ASC; incubating the droplets of step a) to accumulate antibodies within the droplets; picoinjecting virus into the droplets of step b) to form immune complex droplets; picoinjecting host cells into the immune complex droplets to form neutralised droplets and infected droplets; and sorting the infected droplets from the neutralised droplets, b based on infection of the host cells by the virus, to assay the ASCs within the neutralised droplets. The present disclosure also concerns a microfluidic platform thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to an anti-human DCBLD2 nano antibody and application thereof. The anti-DCBLD2 nano antibody is successfully screened by using a phage display technology, and the nano antibody can be specifically combined with human DCBLD2 protein, can be prepared into an immune complex or a pharmaceutical composition for preventing or treating DCBLD2 target related diseases, and has a wide application prospect.

A method for quantifying at least a first glycosylated analyte having a first glycan moiety and a first protein moiety, in a sample using an immunoassay, includes contacting the sample with a plurality of first magnetic particles, and a first antibody or an antigen-binding fragment thereof specific for said first protein moiety, labelled with a reactive enzyme; allowing the first magnetic particles to capture the first glycosylated analyte; allowing the first antibody or the antigen-binding fragment thereof to form a first immunocomplex with the captured first glycosylated analyte; separating captured analytes from any uncaptured analytes and unbound antibodies or antigen-binding fragments thereof; adding a first substrate and allowing it to react with the reactive enzyme of the labelled first antibody; measuring the intensity of the first detectable signal; and correlating the measured intensity of the first detectable signal to the quantity of the first glycosylated analyte in the sample.

The invention belongs to the technical field of optical biosensors, and particularly relates to an ultralow-concentration Fabry-Perot microcavity biosensor. The sensing microcavity comprises a square capillary quartz tube, and the upper surface and the lower surface of the square capillary quartz tube are plated with high-reflectivity films; a liquid core area of the square tube is a micro-flow channel, and a polyethylene glycol polymerization promoting biomolecule solution is introduced into the micro-flow channel, so that the Fabry-Perot microcavity biosensor is obtained. According to the invention, the square capillary quartz tube provides high-precision parallelism between the two reflectors, so that diffraction and walk-off loss can be reduced, the mode volume in the cavity can be reduced, the light energy density can be increased, strong interaction between light and substances can be realized, and the quality factor can be improved; polyethylene glycol can promote the polymerization of biomolecular protein, enhance the reaction of an antigen-antibody compound, and further promote the aggregation of an immune compound. The biosensor is simple in structure, convenient to prepare, good in repeatability and stability, high in response speed and free of surface modification and chemical labeling.

The invention provides an aldosterone antigen binding molecule and application thereof, and relates to the technical field of biology. The aldosterone antigen binding molecule is selected from a first antigen binding molecule containing CDR sequences as shown in SEQ ID NO.1 and SEQ ID NO.2 or a second antigen binding molecule containing CDR sequences as shown in SEQ ID NO.3 and SEQ ID NO.4. The aldosterone antigen binding molecule can bind an aldosterone antigen, and can be used for a method or a product for detecting aldosterone based on an immunological principle; the first antigen binding molecule and the second antigen binding molecule can also form an immune complex with a double-antibody sandwich structure with aldosterone, so that aldosterone is detected by a double-antibody sandwich principle.

The invention relates to an SERS (Surface Enhanced Raman Scattering) immune probe and a preparation method thereof as well as an SERS immune detection method and application thereof. The preparation method of the SERS immune probe comprises the following steps: (1) synthesizing Pd-Au-Ag NCs: taking a silver nanocube as a sacrificial template, and preparing the Pd-Au-Ag NCs through a couple replacement reaction; and (2) modification: marking 4-mercaptobenzoic acid on the surface of the Pd-Au-Ag NCs, and coupling anti-human IgG (Immunoglobulin G) to obtain the SERS immune probe. According to the SERS immune probe and the preparation method thereof as well as the SERS immune detection method and application thereof, the targeted SERS immune probe is prepared, porous silicon for forming an immune substrate by fixing CCP is taken as a substrate, and Anti-CCP is combined with the immune probe after the immune substrate captures Anti-CCP, so that a sandwich immune compound is formed, and the SERS immune probe is used for detecting the anti-CCP in the SERS immune probe. Therefore, the immunodetection method has excellent reproducibility and sensitivity.

Disclosed herein is a method for treating immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) with the factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof (e.g., iptacopan hydrochloride).

This invention discloses a quantitative test strip for HBV PreS1 antibody based on the AIE molecule, its preparation method, and its applications, relating to the fields of molecular biology, immunology, and biodetection technology. The test strip includes a sample pad, a labeling pad, a nitrocellulose membrane (NC membrane), an absorbent pad, and a base plate. The NC membrane detection line is coated with HBV PreS1 antigen to capture PreS1 antibodies in the sample. The labeling pad contains an immobilized Anti-Human IgG antibody conjugated to the AIE molecule, which binds to the PreS1 antibodies in the sample to form an immune complex. The test strip of this invention enables rapid detection of PreS1 antibodies and achieves enhanced fluorescence in the detection results. Combined with a fluorescence reader or fluorescence card reader, the detection results can be digitally and quantitatively analyzed. It is simple to operate, rapid in detection, and significantly improves detection sensitivity and enables quantitative analysis.

The invention relates to a preparation method of a CpG ODN nano immune complex, which comprises the following steps: (1) uniformly mixing a protamine solution with a certain concentration and a CpG motif-containing oligodeoxynucleotide CpG ODN aqueous solution with a certain concentration according to a certain ratio, and carrying out electrostatic compounding assembly at room temperature to form a suspension; and (2) applying energy to the suspension to disperse / homogenize uniformly to form the suspension of the nano-composite. The nano-composite prepared by the method disclosed by the invention is controllable in particle size and controllable in surface charge. The nano particles formed under the preparation condition of an optimized proportion are uniformly dispersed, good in stability, good in resolubility after freezing, and good in long-term storage stability. The preparation method provided by the invention is simple, does not involve toxic and harmful chemical substances, and is suitable for amplification. Compared with the prior art, the preparation method provided by the invention can obviously improve the effective concentration of the effective active substance CpG ODN in the nano immune complex. The invention also relates to the nano immune complex prepared by the method and application thereof. Cell and animal experiments prove that the nano immune complex prepared by the method has good immunostimulatory activity, can stimulate the maturation of related immune cells and induce the secretion of related cytokines, can be independently used as an immunomodulator, and can also be used as an immunologic adjuvant to be combined with various antigens to be used as a vaccine preparation as a whole. The nano immune complex has good application prospects in the fields of inducing and activating immune cells to mature, releasing cytokines, resisting allergic diseases, preventing and treating microbial infectious diseases, vaccine adjuvants, resisting tumor immunotherapy and resisting Alzheimer's disease.

Aspects of the disclosure provide for devices and methods of use thereof for detecting the presence of 14-3-3η protein in capillary blood samples from subjects suspected of having or at risk of developing arthritic conditions. In an example, a method includes obtaining a capillary blood sample from such a subject, and applying the capillary blood sample to a lateral flow device under conditions sufficient for formation of an immunocomplex comprising an immobilized anti-14-3-3η antibody coupled to a 14-3-3η protein that is further coupled to a labeled anti-14-3-3η antibody, wherein formation of the immunocomplex, and visualization thereof, is indicative of the arthritic condition.

In certain embodiments, the present invention provides a method for detecting an anti-drug antibody (ADA) in a sample, comprising: a) pre-treating the sample at a high temperature to dissociate the ADA: drug immune complex in the sample; b) isolating the ADA from the sample by a matrix; c) retrieving the ADA from the matrix using a buffer, and d) detecting the ADA in a cell-based assay or an in vitro assay.

The invention belongs to the technical field of genetic engineering antibodies, and particularly relates to an antibody for non-competitive detection of aflatoxin B1 and application of the antibody. The antibody comprises a nano antibody of an anti-aflatoxin B1 antigen-antibody immune complex and a monoclonal antibody of the anti-aflatoxin B1; the amino acid sequence of the nano antibody of the anti-aflatoxin B1 antigen-antibody immune complex is as shown in SEQ ID NO. 1; the monoclonal antibody for resisting aflatoxin B1 comprises a heavy chain and a light chain; the amino acid of the heavy chain is as shown in SEQ ID NO.10, and the amino acid of the light chain is as shown in SEQ ID NO.11. The antibody for non-competitive detection of aflatoxin B1 provided by the invention is low in cost, can be prepared on a large scale through a prokaryotic expression system, is simple and convenient to prepare, has strong operability, and can be applied to non-competitive immunological analysis of aflatoxin B1.

Described herein are methods of treating immune complex mediated membrane proliferative glomerulonephritis (IC-MPGN) with a factor B inhibitor ipropam or a pharmaceutically acceptable salt thereof, e.g., ipropam hydrochloride.

Novel binding molecules comprising humanized antibodies, fragments, variants, and derivatives thereof, as well as compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FX1 and FX1a. The binding molecules are capable of binding to the factor X1A2 domain and forming immune complexes, thereby disrupting the contact activation molecule complex without affecting the activity or activation of hemostatic factor XI. The binding molecules disclosed herein are suitable for safely inhibiting thrombosis and inflammation without impairing hemostasis. Thus, the binding molecules, compositions, methods, and kits provided herein are intended for treating diseases and conditions, particularly those associated with thrombosis and inflammation. In addition, polynucleotides encoding the binding molecules disclosed herein, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are also provided.

An immunoassay method and system, the method comprising: a detection step, comprising providing a test solution containing a carrier immune complex, the carrier immune complex comprising a solid phase carrier, a luminescent material and a test object, under the action of a sheath flow, the test solution flows through a detection zone, and a scattering signal M of the solid phase carrier and a luminescent signal N of the luminescent material in the detection zone are collected; a calculation step, comprising calculating the concentration of the test object in the test solution according to the scattering signal M collected from the solid phase carrier and the luminescent signal N collected from the luminescent material. The present invention realizes digital segmentation from a physical principle through hydraulic focusing, does not require microplate consumables, and at the same time uses less solid phase carriers, is convenient and easy to obtain, and can achieve a dynamic detection range of 5 orders of magnitude.

The present invention relates to a biochemical assay method, which uses a hapten-fixed test probe and reagents repeatedly to quantify analytes in different samples or measure kinetic binding in different samples while maintaining acceptable assay performance, for any number of about 3 to 20 times. The method uses a conjugate solution comprising (i) an anti-hapten antibody and a capture antibody against the analyte or (ii) an anti-hapten antibody and streptavidin in each cycle, and after each reaction cycle, the hapten-coated test probe is regenerated by immersing the test probe in an acidic solution with a pH of about 1 to 4 and optionally further immersing it in a DMSO solution. The robustness of the hapten-fixed solid phase allows the use of denaturing reagents to efficiently elute immune complexes after each cycle without reducing the binding activity of the hapten on the solid phase.

The application relates to a preparation method and application of a sandwich type photoelectrochemical immunosensor based on a Bi2S3 / BiOCl composite material, and belongs to the field of novel functional materials and biosensing detection technology; the Bi2S3 / BiOCl composite material is used as a base material, and visible light is used as a light source to obtain a photoelectric current; the two components of the base material are well matched in bands, greatly improving photoelectric conversion efficiency, so that a large output signal is obtained; different concentrations of the NSE solution to be measured result in different amounts of immune complexes, further resulting in different degrees of influence on photoelectric signals; the sensor shows high sensitivity, a wide detection range and a low detection limit to target objects, can realize rapid and sensitive determination of NSE in human serum, and has great application value for judging diseases of patients in the clinic.

An artificial immune complex (IC) free in solution, the artificial IC comprising a nucleic acid (NA) folding comprising stapled NA strands, the NA folding having an outer surface patterned with addressable sites and epitopes bound to the addressable sites and displayed in three dimensions for recruiting antibodies free in solution.

The application discloses a preparation method of a photoelectrochemical immunosensor for detecting carcinoembryonic antigen + The signal amplification strategy of liposomes and Bi2S3@BiOI heterojunction as a base material are used to successfully construct a PEC immunosensor of Bi2S3@BiOI / Ag2S ternary heterojunction, and the PEC immunosensor is used for detecting the content of carcinoembryonic antigen. Specifically, a sandwich immunocomplex is formed through specific recognition of the aptamer fixed on the magnetic beads, the aptamer labeled on the liposomes and CEA, methanol as a demulsifier is added, the liposomes are broken to release a large number of signal molecules Ag + . The released Ag + is transferred to the surface of the electrode modified by Bi2S3@BiOI to form Ag2S with a narrow band gap in situ, the ternary heterojunction of Bi2S3@BiOI / Ag2S is formed due to the existence of the energy level matching relationship, the light absorption range is expanded, the separation of photoinduced electron-hole pairs is accelerated, the photocurrent signal is enhanced, and the purpose of signal amplification is achieved.

Compositions, kits, systems, and methods for determining a total TSH concentration in a biological sample and / or determining the presence, severity, and / or predisposition of thyroid disease and / or pituitary disorder in an individual are disclosed. The compositions, kits, systems, and methods utilize at least three antibodies or antigen-binding fragments thereof that specifically bind to TSH, wherein at least one of the three antibodies or antigen-binding fragments thereof specifically binds to a TSH variant so that at least antibody-TSH-antibody sandwich immunocomplexes and antibody-TSH variant-antibody sandwich immunocomplexes can be formed. The methods include determining an amount of total TSH present in the biological sample based on the amount of the two sandwich immunocomplexes formed.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.